Watson confirms Actavis acquisition in deal set to take group revenues to $8bn this year
This article was originally published in Scrip
With an upfront payment of €4.25 billion ($5.6 billion) and up to €250 million in future common stock to acquire the private Swiss firm Actavis Group, Watson Pharmaceuticals is now the third largest global generics company with anticipated 2012 pro forma revenues of $8 billion.
You may also be interested in...
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.